Merck U.S. patent rights for products

In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Merck's rights in U.S. patents associated with the relevant product. This list may be a subset of Merck's rights in U.S. patents directed to the relevant product.

Activyl®
(indoxacarb)
U.S. Patent No. 8,475,818

BRAVECTO®
(fluralaner)
U.S. Patent No. 7,662,972
U.S. Patent No. 8,796,464
U.S. Patent No. 8,022,089
U.S. Patent No. 8,492,311
U.S. Patent No. 9,173,870
U.S. Patent No. 9,532,978

BRAVECTO® Plus
(fluralaner and moxidectin) Topical Solution
U.S. Patent No. 9,173,870
U.S. Patent No. 9,532,978

FORTEGRA®
Live eimeria vaccine
U.S. Patent No. 9,050.281

INNOVAX™ ND-IBD
Live virus poultry vaccine
U.S. Patent No. 10,308,956

INNOVAX™ ND-ILT
Live virus poultry vaccine
U.S. Patent No. 8,932,604

Nobivac®: Canine Flu Bivalent
Canine influenza virus
U.S. Patent No. 7,959,929
U.S. Patent No. 9,345,758
U.S. Patent No. 8,246,962

Nobivac®: Canine Flu H3N8
Canine influenza virus
U.S. Patent No. 7,959,929
U.S. Patent No. 9,345,758

Nobivac®: Lyme
Borrelia Burgdorferi Bacterin
U.S. Patent No. 8,137,678
U.S. Patent No. 8,414,901

Nuflor Gold®
Florfenicol
U.S. Patent No. 8,034,845

Posatex® Otic Suspension
Orbifloxacin, Mometasone Furoate monohydrate and Posaconazole, Suspension
U.S. Patent No. 8,084,445
U.S. Patent No. 8,609,645

Prestige® V+ WNV with Havlogen®
ENCEPHALOMYELITIS-RHINOPNEUMONITIS-INFLUENZA-WEST NILE VIRUS VACCINE, C31Eastern and Western Killed Virus, Killed Flavivirus Chimera
U.S. Patent No. 8,048,459
U.S. Patent No. 8,133,712

Resflor Gold®
Florfenicol and Flunixin Meglumine
U.S. Patent No. 6,787,568
U.S. Patent No. 6,790,867
U.S. Patent No. 8,044,102

Vision® 8 Somnus with SPUR®
Clostridium Chauvoei-Septicum-Haemolyticum-Novyi-Sordellii-Perfringens Types C&D-Haemophilus Somnus Bacterin-Toxoid with SPUR
U.S. Patent No. 6,743,430

Zilmax®
Zilpaterol hydrochloride
U.S. Patent No. 8,580,772
U.S. Patent No. 7,207,289

Zuprevo®
Tildipirosin
U.S. Patent No. 6,514,946
U.S. Patent No. 8,227,429

Revised Date: 3/9/20

BELSOMRA®
(suvorexant) Tablets
U.S. Patent No. 7,951,797
U.S. Patent No 10,098,892

BRIDION®
(sugammadex sodium injection) For intravenous use
U.S. Patent No. RE44,733

CLARINEX-D® 12 HOUR
Extended Release Tablets (desloratadine/ pseudoephedrine sulfate) for oral use
U.S. Patent No. 6,709,676
U.S. Patent No. 7,618,649

CLARINEX-D® 24 HOUR
Extended Release Tablets (desloratadine/ pseudoephedrine sulfate) for oral use
U.S. Patent No. 7,618,649

CLARINEX®
RediTabs (desloratadine) for oral use
U.S. Patent No. 7,618,649

DELSTRIGO™
(doravirine/lamivudine/tenofovir disoproxil fumarate) Tablets
U.S. Patent No. 8,486,975
U.S. Patent No.10,603,282

DIFICID®
(fidaxomicin) Tablets for oral use
U.S. Patent No. 8,586,551
U.S. Patent No. 7,863,249
U.S. Patent No. 7,378,508

EMEND®
(aprepitant) Capsules 125/80 mg
U.S. Patent No. 8,258,132

EMEND®
(aprepitant) Capsules 40mg
U.S. Patent No. 8,258,132

EMEND®
(aprepitant) for oral suspension (125 mg)
U.S. Patent No. 8,258,132

INTRON® A
Interferon alfa-2b, recombinant For Injection Powder for Injection
U.S. Patent No. 6,610,830

INTRON® A
Interferon alfa-2b, recombinant For Injection Solution in Multidose Pens for Injection
U.S. Patent No. 6,610,830

INTRON® A
Interferon alfa-2b, recombinant For Injection Solution Vials for Injection
U.S. Patent No. 6,610,830

ISENTRESS®
(raltegravir) Chewable Tablets for oral use
U.S. Patent No. 7,169,780
U.S. Patent No. 7,754,731

ISENTRESS®
(raltegravir) Film-coated Tablets for oral use
U.S. Patent No. 7,169,780
U.S. Patent No. 7,754,731

JANUMET®
(sitagliptin/metformin HCl) Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873

JANUMET® XR
(sitagliptin and metformin HCl extended-release) Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873

JANUVIA®
(sitagliptin) Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708

JUVISYNC
(sitagliptin and simvastatin) Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
U.S. Patent No. 8,168,637

KEYTRUDA®
(pembrolizumab) For Injection
U.S. Patent No. 8,354,509
U.S. Patent No. 8,900,587

NEXPLANON®
(etonogestrel) Implant
U.S. Patent No. 8,722,037

PegIntron®
(Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use REDIPEN®
U.S. Patent No. 6,610,830

PegIntron®
(Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use Single-Use Vial (with 1.25 mL diluent)
U.S. Patent No. 6,610,830

PIFELTRO™
(Doravirine) Tablets
U.S. Patent No. 8,486,975

PREVYMIS™
(letermovir) injection, for intravenous use
U.S. Patent No. RE46,791
U.S. Patent No. 8,513,255

PREVYMIS™
(letermovir) Tablets, for Oral Use
U.S. Patent No. RE46,791
U.S. Patent No. 8,513,255

RECARBRIO®
(imipenem/cilastatin and relebactam) For intravenous use
U.S. Patent No. 8,487,093

SEGLUROMET™
(ertugliflozin and metformin) Tablets for oral use
U.S. Patent No. 8,080,580

SIVEXTRO®
(tedizolid phosphate) Powder for Infusion and Oral tablets
U.S. Patent No. 7,816,379
U.S. Patent No. 8,420,676

STEGLATRO™
(ertugliflozin) Tablets for oral use
U.S. Patent No. 8,080,580

STEGLUJAN™
(ertugliflozin and sitagliptin) Tablets for oral use
U.S. Patent No. 8,080,580

SYLATRON™
(peginterferon alfa-2b) for injection, for subcutaneous use Lyophilized powder in single-use vial
U.S. Patent No. 6,610,830

TEMODAR®
(temozolomide) for Injection
U.S. Patent No. 6,987,108
U.S. Patent No. 7,786,118
U.S. Patent No. 8,623,868

ZEPATIER®
(elbasvir/grazoprevir) Tablets for oral use
U.S. Patent No. 8,871,759
U.S. Patent No. 7,973,040

ZERBAXA®
(ceftolozane sulfate/tazobactam sodium) Powder for infusion
U.S. Patent No. 7,129,232

ZINPLAVA™
(bezlotoxumab) Injection, for intravenous use
U.S. Patent No. 8,257,709

ZOLINZA®
(vorinostat) Capsules
U.S. Patent No. 7,456,219
U.S. Patent No. 7,652,069
U.S. Patent No. 7,851,509
U.S. Patent No. 8,093,295

Revised Date: 3/9/20

ERVEBO®
EBOLA ZAIRE VACCINE, LIVE
U.S. Patent No. 8,012,489B2

GARDASIL®
HUMAN PAPILLOMAVIRUS QUADRIVALENT (TYPES 6, 11, 16, 18) VACCINE, RECOMBINANT
U.S. Patent No. 7,476,389

GARDASIL®9
HUMAN PAPILLOMAVIRUS 9-VALENT VACCINE, RECOMBINANT
U.S. Patent No. 7,476,389

Revised Date: 3/9/20